Impact of cytochrome P450 2C19 genetype polymorphism on voriconazole trough concentration in Chinese adult patients with invasive pulmonary aspergillosis: a prospective multicenter research

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-ONC-14004339

Enrollment

Unknown

Registered

2014-02-25

Start date

2014-06-25

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

invasive pulmonary aspergillosis

Interventions

Patients with invasive pulmonary aspergillosis and No intervention:No intervention

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Proven, probable, or possible invasive pulmonary aspergillosis (IPA); Acute IPA defined as duration of clinical syndrome of <30 days; Treatment with voriconazole; At least 18 years and older; Weight 40 kg to 120 kg; Given the informed consent.

Exclusion criteria

Exclusion criteria: Patients allergic to azole(s); Patients who heve been prescribed voriconazole before; Positive urine pregnancy test (if female); Patients with aspergilloma or chronic aspergillosis ( >1 month duration); Anticipated survival of less than 5 days or Karnofsky score <=20.

Design outcomes

Primary

Measure	Time frame
Genotyping of CYP2C19;voriconazole trough concentration;Serum galactomannan (GM) test;Serum galactomannan (GM) test;MIC of aspergillosis strains to voriconazole;Mortality;lenth of hospitalization;Success rate of therapy;	—

Countries

China

Contacts

Public ContactShifang Ding

Qilu Hospital, Shandong University

dingshifang@sdu.edu.cn+86 18560081003

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026